Inocras raised an additional $31 million in a Series B-3 financing round to expand clinical genome sequencing operations and its proprietary bioinformatics platform. The company said it plans to increase whole-genome sequencing capacity in the U.S., grow commercial and operational capabilities, and expand adoption of its diagnostic offerings. Inocras previously launched two WGS-based tests—CancerVision for solid tumors and RareVision for rare disease—using its bioinformatic pipelines, and said its whole-genome sequencing test is used by more than 100 cancer institutions across Asia. The round, which brings total funding to about $100 million, signals continued investor focus on bringing pan-genomic diagnostics into clinical workflows where sample-to-insight pipelines and evidence generation remain decisive for scaling.